Karyopharm Therapeutics Inc
KPTI5.410USD
-0.320-5.58%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
46.78MMarket Cap
LossP/E TTM
More Details of Karyopharm Therapeutics Inc Company
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. It is developing and commercializing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, mycosis fungoides (MF) and diffuse large B-cell lymphoma (DLBCL). The Company’s product candidate, eltanexor, oral SINE compound that, like selinexor, selectively blocks the nuclear export protein XPO1.
Company Info
Ticker SymbolKPTI
Company nameKaryopharm Therapeutics Inc
IPO dateNov 06, 2013
CEOMr. Richard A. Paulson
Number of employees279
Security typeOrdinary Share
Fiscal year-endNov 06
Address85 Wells Avenue
CityNEWTON
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code02459
Phone16176580600
Websitehttps://karyopharm.com/
Ticker SymbolKPTI
IPO dateNov 06, 2013
CEOMr. Richard A. Paulson
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Michael Mano, J.D.
Mr. Michael Mano, J.D.
Senior Vice President, General Counsel, Secretary
Senior Vice President, General Counsel, Secretary
12.28K
+3.18%
Mr. Stuart Poulton
Mr. Stuart Poulton
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
8.61K
+6.00%
Dr. Reshma Rangwala, M.D., Ph.D.
Dr. Reshma Rangwala, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
7.24K
+8.01%
Mr. Barry E. Greene
Mr. Barry E. Greene
Lead Independent Director
Lead Independent Director
907.00
--
Ms. Sohanya Cheng
Ms. Sohanya Cheng
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
--
--
Mr. Garen G. Bohlin
Mr. Garen G. Bohlin
Independent Director
Independent Director
--
--
Mr. Chen Schor, CPA
Mr. Chen Schor, CPA
Independent Director
Independent Director
--
--
Mr. Richard A. Paulson
Mr. Richard A. Paulson
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Brendan Strong
Mr. Brendan Strong
Senior Vice President - Investor Relations and Corporate Communications
Senior Vice President - Investor Relations and Corporate Communications
--
--
Ms. Lori Macomber, CPA
Ms. Lori Macomber, CPA
Executive Vice President, Chief Financial Officer, Treasurer
Executive Vice President, Chief Financial Officer, Treasurer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Michael Mano, J.D.
Mr. Michael Mano, J.D.
Senior Vice President, General Counsel, Secretary
Senior Vice President, General Counsel, Secretary
12.28K
+3.18%
Mr. Stuart Poulton
Mr. Stuart Poulton
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
8.61K
+6.00%
Dr. Reshma Rangwala, M.D., Ph.D.
Dr. Reshma Rangwala, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
7.24K
+8.01%
Mr. Barry E. Greene
Mr. Barry E. Greene
Lead Independent Director
Lead Independent Director
907.00
--
Ms. Sohanya Cheng
Ms. Sohanya Cheng
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
--
--
Mr. Garen G. Bohlin
Mr. Garen G. Bohlin
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Tue, Aug 19
Updated: Tue, Aug 19
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
T. Rowe Price Investment Management, Inc.
8.40%
The Vanguard Group, Inc.
5.98%
J. Wood Capital Advisors LLC
5.28%
Adage Capital Management, L.P.
4.86%
Eversept Partners, LP
2.97%
Other
72.51%
Shareholders
Shareholders
Proportion
T. Rowe Price Investment Management, Inc.
8.40%
The Vanguard Group, Inc.
5.98%
J. Wood Capital Advisors LLC
5.28%
Adage Capital Management, L.P.
4.86%
Eversept Partners, LP
2.97%
Other
72.51%
Shareholder Types
Shareholders
Proportion
Investment Advisor
20.86%
Hedge Fund
16.35%
Research Firm
7.96%
Corporation
5.28%
Investment Advisor/Hedge Fund
4.11%
Venture Capital
1.83%
Individual Investor
1.14%
Bank and Trust
0.03%
Other
42.45%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
284
4.20M
48.66%
-1.75M
2025Q1
308
4.25M
49.43%
-1.53M
2024Q4
324
4.68M
55.67%
-1.51M
2024Q3
341
4.98M
60.06%
-2.16M
2024Q2
356
5.56M
67.54%
-2.08M
2024Q1
352
5.60M
72.46%
-1.99M
2023Q4
354
5.60M
73.31%
-2.02M
2023Q3
365
5.88M
77.33%
-1.69M
2023Q2
380
6.19M
81.48%
-2.04M
2023Q1
395
6.56M
86.55%
-1.62M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
T. Rowe Price Investment Management, Inc.
139.65K
1.62%
+139.65K
--
Mar 31, 2025
The Vanguard Group, Inc.
510.29K
5.91%
-5.00
-0.00%
Mar 31, 2025
J. Wood Capital Advisors LLC
458.13K
5.3%
--
--
Apr 10, 2025
Adage Capital Management, L.P.
421.32K
4.88%
-1.00
-0.00%
Mar 31, 2025
Eversept Partners, LP
257.15K
2.98%
+117.90K
+84.67%
Mar 31, 2025
J.P. Morgan Securities LLC
147.42K
1.71%
+129.01K
+700.61%
Mar 31, 2025
Citadel Advisors LLC
206.91K
2.39%
-2.00
-0.00%
Mar 31, 2025
Palo Alto Investors LP
324.03K
3.75%
-3.10K
-0.95%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
188.02K
2.18%
-1.00K
-0.53%
Mar 31, 2025
BofA Global Research (US)
132.91K
1.54%
+122.13K
+1132.80%
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Feb 24, 2025
Merger
15→1
Feb 24, 2025
Merger
15→1
Feb 24, 2025
Merger
15→1
Feb 24, 2025
Merger
15→1
Date
Type
Ratio
Feb 24, 2025
Merger
15→1
Feb 24, 2025
Merger
15→1
Feb 24, 2025
Merger
15→1
Feb 24, 2025
Merger
15→1
